In treatment-naïve patients with vision impairment due to DME

START STRONG

STAY STRONG

Vision gains

Rapid, early vision gains in Year 1, maintained through to Year 31,2

Read more

EURETINA guidelines

EYLEA® is the EURETINA guidelines DME drug of choice in patients with baseline BCVA <69 letters3,a
Superior to ranibizumab in Year 13,4

Read more

Anti-VEGF Cochrane meta-analysis

DME patients are 30% more likely to gain ≥3 lines vs. ranibizumab in Year 15,b,c

Read more

a These EURETINA Guidelines included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US-approved dosage), while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.
b Meta-analysis using Cochrane methods (based on a search of databases conducted in April 2017) of RCTs with anti-VEGF agents in DME patients, focused on the three most commonly used drugs: EYLEA, ranibizumab and unlicensed bevacizumab. The analysis included 24 studies and 6007 eyes in total. 17 studies (4031 eyes) were assessed for VA data.
c This Cochrane meta-analysis included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US approved dosage) while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.

BCVA, best-corrected visual acuity; DME, diabetic macular edema; Q8, 2 mg every-8-weeks; RCT, randomized controlled trial; VA, visual acuity.

References

  1. Korobelnik J-F, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
  2. Heier JS, Korobelnik JF, Brown DM. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016;123(11):2376-2385.
  3. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222.
  4. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
  5. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419.